Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 Monoclonal Antibody (mAb) GSK2849330 and Characterize Its Dose-receptor Occupancy Relationship in Subjects With Advanced HER3-Positive Solid Tumors

NCT02345174 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02345174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02345174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 Monoclonal Antibody (mAb) GSK2849330 and Characterize Its Dose-receptor Occupancy Relationship in Subjects With Advanced HER3-Positive Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2015
Completion date
June 2, 2016
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neoplasms